

# Joanna C Robson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6194923/publications.pdf>

Version: 2024-02-01

63  
papers

2,161  
citations

279487

23  
h-index

243296

44  
g-index

64  
all docs

64  
docs citations

64  
times ranked

1734  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinicopathologic Associations in a Large International Cohort of Patients With Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2022, 74, 1013-1018.	1.5	4
2	Patient reported outcomes in systemic vasculitis. <i>Current Opinion in Rheumatology</i> , 2022, 34, 33-38.	2.0	5
3	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 386-392.	2.9	50
4	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 309-314.	0.5	157
5	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 393-399.	2.9	71
6	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 321-326.	0.5	112
7	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 400-406.	2.9	62
8	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 315-320.	0.5	145
9	Response to: Correspondence on a€ 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitisâ€™™ by Joanna C Robson <i>et al</i> and â€™™2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitisâ€™™ by Ravi Suppiah <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2022, <a href="#">annrheumdis.2022.222362</a> .	0.5	12
10	P301â€™™fPatient reported outcome measure for giant cell arteritis: clinical testing. <i>Rheumatology</i> , 2022, 61, .	0.9	0
11	P092â€™™fPatientsâ€™™ perceptions of glucocorticoid therapy impact on health-related quality of life during treatment for rheumatic diseases: international development of a treatment-specific patient-reported outcome measure (the Steroid PRO). <i>Rheumatology</i> , 2022, 61, .	0.9	0
12	ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 2567-2582.	1.6	19
13	OA23â€™™fPatient-reported outcome measure for giant cell arteritis: cross-sectional validation study. <i>Rheumatology</i> , 2022, 61, .	0.9	0
14	P293â€™™fTocilizumab for refractory or relapsing giant cell arteritis: audit data from the Bristol and Bath regional multidisciplinary meetings 2018-2021. <i>Rheumatology</i> , 2022, 61, .	0.9	0
15	The patient perspective of nurseâ€™™led care in early rheumatoid arthritis: A systematic review of qualitative studies with thematic analysis. <i>Journal of Clinical Nursing</i> , 2021, 30, 145-160.	1.4	12
16	Patient perceptions of health-related quality of life in giant cell arteritis: international development of a disease-specific patient-reported outcome measure. <i>Rheumatology</i> , 2021, 60, 4671-4680.	0.9	11
17	Pulmonary involvement in primary systemic vasculitides. <i>Rheumatology</i> , 2021, 61, 319-330.	0.9	16
18	Patient perceptions of physical activity after a diagnosis of Giant Cell Arteritis: analysis of multinational qualitative data. <i>Arthritis Care and Research</i> , 2021, , .	1.5	1

#	ARTICLE	IF	CITATIONS
19	Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1139-1145.	1.6	8
20	Patient Reported Outcomes in Large Vessel Vasculitides. <i>Current Rheumatology Reports</i> , 2021, 23, 7.	2.1	2
21	The Patients' Perspective of Important Glucocorticoid Effects. <i>Journal of Clinical Rheumatology</i> , 2021, 27, 232-238.	0.5	5
22	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2020, 72, 1615-1624.	1.5	77
23	Diagnostic Assessment Strategies and Disease Subsets in Giant Cell Arteritis: Data From an International Observational Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 667-676.	2.9	33
24	Psychological and self-management support for people with vasculitis or connective tissue diseases: UK health professionals' perspectives. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa016.	0.3	1
25	The patient's perspective of the adverse effects of glucocorticoid use: A systematic review of quantitative and qualitative studies. From an OMERACT working group. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 996-1005.	1.6	14
26	Feasibility and Face Validity of Outcome Measures for Use in Future Studies of Polymyalgia Rheumatica: An OMERACT Study. <i>Journal of Rheumatology</i> , 2020, 47, 1379-1384.	1.0	10
27	Mixed methods study of clinicians' perspectives on barriers to implementation of treat to target in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1031-1036.	0.5	13
28	Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines' Executive summary. <i>Rheumatology</i> , 2020, 59, 727-731.	0.9	5
29	Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. <i>Rheumatology</i> , 2020, 59, e24-e32.	0.9	42
30	Early development of new cardiovascular risk factors in the systemic vasculitides. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 126-134.	0.4	2
31	Toward a Core Domain Set for Glucocorticoid Impact in Inflammatory Rheumatic Diseases: The OMERACT 2018 Glucocorticoid Impact Working Group. <i>Journal of Rheumatology</i> , 2019, 46, 1179-1182.	1.0	8
32	Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018. <i>Journal of Rheumatology</i> , 2019, 46, 1198-1201.	1.0	24
33	Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes. <i>Patient Related Outcome Measures</i> , 2019, Volume 10, 37-42.	0.7	9
34	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2019, 46, 928-934.	1.0	6
35	The OMERACT Emerging Leaders Program: The Good, the Bad, and the Future. <i>Journal of Rheumatology</i> , 2019, 46, 1047-1052.	1.0	5
36	Updating OMERACT Core Set of Domains for ANCA-associated Vasculitis: Patient Perspective Using the International Classification of Function, Disability, and Health. <i>Journal of Rheumatology</i> , 2019, 46, 1415-1420.	1.0	7

#	ARTICLE	IF	CITATIONS
37	Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2018, 70, 1373-1384.	1.5	54
38	Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212713.	0.5	38
39	Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Rheumatology International</i> , 2018, 38, 675-682.	1.5	40
40	Introduction, epidemiology and classification of vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 3-20.	1.4	69
41	Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure. <i>Patient Related Outcome Measures</i> , 2018, Volume 9, 17-34.	0.7	24
42	Health-related outcomes of importance to patients with Takayasu's arteritis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 111, 51-57.	0.4	6
43	The association of vascular risk factors with visual loss in giant cell arteritis. <i>Rheumatology</i> , 2017, 56, kew397.	0.9	16
44	Are the 1990 American College of Rheumatology vasculitis classification criteria still valid?. <i>Rheumatology</i> , 2017, 56, 1154-1161.	0.9	89
45	A Patient-reported Outcome Measure for Effect of Glucocorticoid Therapy in Adults with Inflammatory Diseases Is Needed: Report from the OMERACT 2016 Special Interest Group. <i>Journal of Rheumatology</i> , 2017, 44, 1754-1758.	1.0	16
46	Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1933-1937.	1.0	33
47	I119.â€fDEVELOPMENT OF A PATIENT-REPORTED OUTCOME MEASURE FOR VASCULITIS. <i>Rheumatology</i> , 2017, 56, 9	0.9	0
48	OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibodyâ€“associated Vasculitis. <i>Journal of Rheumatology</i> , 2017, 44, 1529-1535.	1.0	25
49	Which Patients with Giant Cell Arteritis Will Develop Cardiovascular or Cerebrovascular Disease? A Clinical Practice Research Datalink Study. <i>Journal of Rheumatology</i> , 2016, 43, 1085-1092.	1.0	24
50	Long-Term Outcome of ANCA-Associated Systemic Vasculitis. , 2016, , 159-171.		1
51	Patient experiences of participation in a medical student teaching workshop. <i>Medical Teacher</i> , 2015, 37, 94-96.	1.0	12
52	Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibodyâ€“associated Vasculitis Using the OMERACT Process. <i>Journal of Rheumatology</i> , 2015, 42, 2204-2209.	1.0	22
53	Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12. <i>Journal of Rheumatology</i> , 2015, 42, 2465-2469.	1.0	33
54	The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 129-135.	0.5	149

#	ARTICLE	IF	CITATIONS
55	Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. <i>Rheumatology</i> , 2015, 54, 471-481.	0.9	104
56	Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 177-184.	0.5	214
57	P10. Review of the expert panel methodology in the diagnostic and classification criteria for vasculitis study: a pilot study. <i>Rheumatology</i> , 2014, 53, i15-i16.	0.9	1
58	Current Status of Outcome Measure Development in Vasculitis. <i>Journal of Rheumatology</i> , 2014, 41, 593-598.	1.0	31
59	ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). <i>Clinical and Experimental Nephrology</i> , 2013, 17, 619-621.	0.7	158
60	The Need for Diagnostic Criteria in Systemic Vasculitis. <i>Current Immunology Reviews</i> , 2011, 7, 394-401.	1.2	0
61	Outcome Measures in ANCA-associated Vasculitis. <i>Rheumatic Disease Clinics of North America</i> , 2010, 36, 587-607.	0.8	12
62	The phagocytic capacity of neurones. <i>European Journal of Neuroscience</i> , 2007, 25, 2947-2955.	1.2	41
63	317. Re-Appraisal of the 1990 American College of Rheumatology Classification Criteria for Systemic Vasculitis: Analysis of Data from the Diagnostic and Classification Criteria in Vasculitis Study. <i>Rheumatology</i> , 0, , .	0.9	0